1. Home
  2. UHG vs SERA Comparison

UHG vs SERA Comparison

Compare UHG & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Homes Group Inc

UHG

United Homes Group Inc

HOLD

Current Price

$1.19

Market Cap

68.8M

ML Signal

HOLD

Logo Sera Prognostics Inc.

SERA

Sera Prognostics Inc.

HOLD

Current Price

$2.35

Market Cap

79.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UHG
SERA
Founded
N/A
2008
Country
United States
United States
Employees
195
N/A
Industry
Homebuilding
Precision Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.8M
79.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
UHG
SERA
Price
$1.19
$2.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
79.1K
54.4K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.32
EPS
N/A
N/A
Revenue
N/A
$81,000.00
Revenue This Year
N/A
$554.81
Revenue Next Year
N/A
$517.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.19
52 Week Low
$0.99
$1.37
52 Week High
$4.78
$4.09

Technical Indicators

Market Signals
Indicator
UHG
SERA
Relative Strength Index (RSI) 40.93 57.85
Support Level $1.15 $2.26
Resistance Level $1.81 $2.41
Average True Range (ATR) 0.02 0.18
MACD 0.02 0.04
Stochastic Oscillator 77.78 92.68

Price Performance

Historical Comparison
UHG
SERA

About UHG United Homes Group Inc

United Homes Group Inc designs, builds and sells homes in high growth markets, including South Carolina, North Carolina, and Georgia. UHG employs a land-light operating, with a focus on the design, construction and sale of entry-level, first, second and third move-up single-family houses. The company principally builds detached single-family houses, and, to a lesser extent, attached single-family houses, including duplex houses and town houses. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Share on Social Networks: